BEGIN:VCALENDAR
VERSION:2.0
PRODID:Linklings LLC
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
X-LIC-LOCATION:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:19700308T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:19701101T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTAMP:20241017T183512Z
LOCATION:Harbor Ballrooms D-I
DTSTART;TZID=America/Los_Angeles:20241017T095500
DTEND;TZID=America/Los_Angeles:20241017T101500
UID:ncs_NCS 2024_sess101_ccrnt141@linklings.com
SUMMARY:Time is Brain: Apixaban and Rivaroxaban Reversal Strategies for In
 tracerebral Hemorrhage Requiring Surgery
DESCRIPTION:Breakout Session\n\nKaylee Marino Hargraves (Brigham and Women
 's Hospital)\n\nThis session will focus on antithrombotic reversal strateg
 ies in patients presenting with an intracerebral hemorrhage on apixaban or
  rivaroxaban. This session will compare and contrast reversal strategies f
 or patients on a direct oral anticoagulant (DOAC) comparing andexanet alfa
  to 4F-PCC as well as evaluating different dosing strategies for 4F-PCC in
 cluding weight based versus fixed dosing. This talk will go in depth evalu
 ating the current literature regarding andexanet alfa versus 4F-PCC for ap
 ixaban and rivaroxaban reversal. This session will evaluate outcomes and r
 eversal strategies for patients undergoing a neurosurgical procedure and h
 ow that may impact the reversal strategy taking into account the type of s
 urgery, length of surgery and level of anticoagulation present prior to su
 rgery. Given the significant cost of andexanet alfa and pharmacokinetic di
 fferences compared to 4F-PCC, discussions regarding addition to formulary,
  development of an institutional anticoagulation reversal guideline, and e
 ducation to hospital staff regarding institutional protocols will be discu
 ssed. Throughout the session, an interactive case will engage the audience
  to apply the knowledge they are learning to real life situations that may
  occur in the hospital setting. Due to the substantial increase in DOAC us
 e in the community, hospitals are seeing an increasing number of patients 
 who present to the ED and ICU setting with an intracerebral hemorrhage on 
 rivaroxaban or apixaban prompting the need for quick, safe, and effective 
 reversal strategies.\n\nTrack: Clinical Practice\n\nFocus Area: Intracereb
 ral Hemorrhage, Ischemic Stroke, Multimodal Neuromonitoring (invasive/non-
 invasive), Nursing Pharmacology, Pharmacist Practice, Stroke, Subarachnoid
  Hemorrhage\n\nTarget Audience: Intermediate, Advanced\n\nSession Chair: A
 ngela Hays Shapshak (University of Alabama at Birmingham)
END:VEVENT
END:VCALENDAR